FDA Warning Letter Lessons for RUO Catalogs

Several FDA warning letters describe products labeled as research-use-only or not for human consumption while also pointing to website content that, in FDA's view, established intended use as drugs for human use.

The practical lesson is direct: the disclaimer and the page content must agree. A product page should not say "research use only" in one section and then discuss human outcomes, treatment goals, weight-management claims, disease states, body-system effects, or administration concepts elsewhere.

For Strand Bio, product pages should stay limited to catalog fields: offered size, molecule class, research category, catalog price, access status, checkout availability, and related catalog records.

FDA warning letters often evaluate more than one product page. They may reference blog posts, social media, downloadable guides, community pages, or other pages that drive visitors back to checkout.

That means a compliant catalog strategy has to apply across the full site:

Research catalogs should not provide dosing, titration, administration, injection, reconstitution, or preparation guidance. Public FDA letters have treated use-oriented supporting content as part of the intended-use picture.

For Strand Bio, this means no dose schedules, no "how to use" instructions, no syringe-volume math, no injection references, no reconstitution walkthroughs, and no clinical protocol language.

A catalog page should not describe a product as a treatment, therapy, supplement, medication, weight-loss product, anti-aging product, or recovery product for people or animals.

Even when a page uses "research" wording, outcome-heavy language can make the page read like a human-use product page. A safer RUO catalog page focuses on procurement fields instead of outcomes.

Warning letters have also pointed to the context in which products are offered. When a site pairs peptide products with injection-oriented accessories, reconstitution products, or administration content, that pairing may affect how the intended use is interpreted.

Strand Bio should avoid content that suggests an end-use workflow. Catalog records should remain catalog records.

Research Library pages can be more useful than product pages, but they still need guardrails. A research article can explain how to compare catalog records, documentation status, access status, shipping policies, and category structure. It should not become a medical, dosing, treatment, or administration guide.

The safest Research Library pages for Strand Bio are pages like:

Every public page should pass this test:

Could this page be useful to compare a research catalog record without telling someone what to do with the material?

If the answer is yes, the page belongs in the Strand Bio content system. If the answer is no, the content should not be published.